XBI250110C105000
- 0.08
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Moderna Analyst Ratings
Neurocrine Biosciences Analyst Ratings
United Therapeutics Analyst Ratings
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Biogen Analyst Ratings
AbbVie Analyst Ratings
Nvidia, Palantir, Ionq, Novavax, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Stocks Sink As Bond Yields Soar, Nvidia Eyes Worst Day In 4 Months, Bitcoin Tumbles To $97,000: What's Driving Markets Tuesday?
Looking Into Gilead Sciences's Recent Short Interest
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Benzinga Market Summary: Bitcoin Falls, Vaccine Stocks Rise On Bird Flu Concerns, NVIDIA Drops
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.
UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Spotlight on Moderna: Analyzing the Surge in Options Activity
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Bird Flu Claims First U.S. Life in Louisiana